Scholarlink

Objective <p>Primary Sjögren’s syndrome-associated peripheral neuropathy (pSS-PN) represents a clinically heterogeneous complication linked to significant morbidity. This study aims to characterize its prevalence, clinical phenotypes, predictive factors, and prognosis.</p> Methods <p>In this retrospective cohort study conducted at Shanghai Tongji Hospital, 553 consecutive pSS patients (2002 American–European Consensus Group criteria) were evaluated. After applying the exclusion criteria, 320 eligible patients completed the full assessment protocol and constituted the final analytical cohort. Based on the diagnostic criteria for peripheral neuropathy (PN), 59 patients were diagnosed with pSS-PN, while the remaining 261 were classified as pSS without PN (pSS-nPN).</p> Results <p>The prevalence of pSS-PN was 18.4% (59/320) in the final cohort. The predominant subtype was distal axonal sensory polyneuropathy (33.9%). Independent predictors included fatigue (OR 2.27, 95% CI 1.27–4.06; <i>p</i> = 0.005), Schirmer’s test ≤ 2&#xa0;mm/5&#xa0;min (OR 2.78, 95% CI 1.62–4.76; <i>p</i> &lt; 0.001), elevated creatine kinase (OR 3.78, 95% CI 1.92–7.45; <i>p</i> &lt; 0.001), ischemic electrocardiogram (ECG) changes (OR 2.17, 95% CI 1.29–3.64;<i> p</i> = 0.003), and pulmonary involvement (OR 6.46, 95% CI 3.70–11.39; <i>p</i> &lt; 0.001).</p> Conclusions <p>Early identification and subtyping of pSS-PN are crucial for accurate disease assessment and guiding treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical spectrum, predictive biomarkers, and prognostic implications of peripheral neuropathies in primary Sjögren’s syndrome: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Yanqing Wang,
  • Jincheng Pu,
  • Fang Han,
  • Chunrui Li,
  • Yan Chen,
  • Yuanyuan Liang,
  • Zhenzhen Wu,
  • Shengnan Pan,
  • Jun Qian,
  • Wei Wang,
  • Jianping Tang,
  • Xuan Wang

摘要

Objective

Primary Sjögren’s syndrome-associated peripheral neuropathy (pSS-PN) represents a clinically heterogeneous complication linked to significant morbidity. This study aims to characterize its prevalence, clinical phenotypes, predictive factors, and prognosis.

Methods

In this retrospective cohort study conducted at Shanghai Tongji Hospital, 553 consecutive pSS patients (2002 American–European Consensus Group criteria) were evaluated. After applying the exclusion criteria, 320 eligible patients completed the full assessment protocol and constituted the final analytical cohort. Based on the diagnostic criteria for peripheral neuropathy (PN), 59 patients were diagnosed with pSS-PN, while the remaining 261 were classified as pSS without PN (pSS-nPN).

Results

The prevalence of pSS-PN was 18.4% (59/320) in the final cohort. The predominant subtype was distal axonal sensory polyneuropathy (33.9%). Independent predictors included fatigue (OR 2.27, 95% CI 1.27–4.06; p = 0.005), Schirmer’s test ≤ 2 mm/5 min (OR 2.78, 95% CI 1.62–4.76; p < 0.001), elevated creatine kinase (OR 3.78, 95% CI 1.92–7.45; p < 0.001), ischemic electrocardiogram (ECG) changes (OR 2.17, 95% CI 1.29–3.64; p = 0.003), and pulmonary involvement (OR 6.46, 95% CI 3.70–11.39; p < 0.001).

Conclusions

Early identification and subtyping of pSS-PN are crucial for accurate disease assessment and guiding treatment.